PROCEPT BioRobotics (PRCT) Competitors

$26.12 0.00 (0.00%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$26.10 -0.02 (-0.06%)

As of 05/15/2026 07:41 PM Eastern

PRCT vs. BLCO, STVN, IRTC, LIVN, and NVST

Should you buy PROCEPT BioRobotics stock or one of its competitors? MarketBeat compares PROCEPT BioRobotics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PROCEPT BioRobotics include Bausch + Lomb (BLCO), Stevanato Group (STVN), iRhythm Technologies (IRTC), LivaNova (LIVN), and Envista (NVST). These companies are all part of the "medical equipment" industry.

How does PROCEPT BioRobotics compare to Bausch + Lomb?

PROCEPT BioRobotics (NASDAQ:PRCT) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

PROCEPT BioRobotics has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.83	-$95.57M	-$1.82	N/A
Bausch + Lomb	$5.21B	1.10	-$360M	-$0.62	N/A

PROCEPT BioRobotics currently has a consensus price target of $41.45, suggesting a potential upside of 58.71%. Bausch + Lomb has a consensus price target of $18.08, suggesting a potential upside of 12.41%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bausch + Lomb has a net margin of -4.21% compared to PROCEPT BioRobotics' net margin of -31.82%. Bausch + Lomb's return on equity of 3.60% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Bausch + Lomb	-4.21%	3.60%	1.69%

PROCEPT BioRobotics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, PROCEPT BioRobotics had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 9 mentions for PROCEPT BioRobotics and 6 mentions for Bausch + Lomb. PROCEPT BioRobotics' average media sentiment score of 0.98 beat Bausch + Lomb's score of 0.11 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PROCEPT BioRobotics beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Stevanato Group?

PROCEPT BioRobotics (NASDAQ:PRCT) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Stevanato Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.83	-$95.57M	-$1.82	N/A
Stevanato Group	€1.34B	4.01	€158.21M	€0.59	30.11

PROCEPT BioRobotics currently has a consensus price target of $41.45, suggesting a potential upside of 58.71%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Stevanato Group has a net margin of 11.76% compared to PROCEPT BioRobotics' net margin of -31.82%. Stevanato Group's return on equity of 10.27% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Stevanato Group	11.76%	10.27%	6.08%

PROCEPT BioRobotics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

In the previous week, PROCEPT BioRobotics had 8 more articles in the media than Stevanato Group. MarketBeat recorded 9 mentions for PROCEPT BioRobotics and 1 mentions for Stevanato Group. PROCEPT BioRobotics' average media sentiment score of 0.98 beat Stevanato Group's score of 0.21 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PROCEPT BioRobotics beats Stevanato Group on 9 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

iRhythm Technologies presently has a consensus target price of $193.38, suggesting a potential upside of 69.64%. PROCEPT BioRobotics has a consensus target price of $41.45, suggesting a potential upside of 58.71%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43

iRhythm Technologies has higher revenue and earnings than PROCEPT BioRobotics. iRhythm Technologies is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.01	-$44.55M	-$0.86	N/A
PROCEPT BioRobotics	$308.05M	4.83	-$95.57M	-$1.82	N/A

iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, PROCEPT BioRobotics had 3 more articles in the media than iRhythm Technologies. MarketBeat recorded 9 mentions for PROCEPT BioRobotics and 6 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.37 beat PROCEPT BioRobotics' score of 0.98 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has a net margin of -3.53% compared to PROCEPT BioRobotics' net margin of -31.82%. iRhythm Technologies' return on equity of -10.26% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

Summary

iRhythm Technologies beats PROCEPT BioRobotics on 13 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to LivaNova?

PROCEPT BioRobotics (NASDAQ:PRCT) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

PROCEPT BioRobotics presently has a consensus target price of $41.45, suggesting a potential upside of 58.71%. LivaNova has a consensus target price of $77.22, suggesting a potential upside of 10.32%. Given PROCEPT BioRobotics' higher probable upside, equities research analysts clearly believe PROCEPT BioRobotics is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

PROCEPT BioRobotics has higher earnings, but lower revenue than LivaNova. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.83	-$95.57M	-$1.82	N/A
LivaNova	$1.39B	2.77	-$242.47M	$1.95	35.90

PROCEPT BioRobotics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, PROCEPT BioRobotics had 6 more articles in the media than LivaNova. MarketBeat recorded 9 mentions for PROCEPT BioRobotics and 3 mentions for LivaNova. LivaNova's average media sentiment score of 0.98 beat PROCEPT BioRobotics' score of 0.98 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 7.48% compared to PROCEPT BioRobotics' net margin of -31.82%. LivaNova's return on equity of 16.48% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
LivaNova	7.48%	16.48%	7.59%

Summary

LivaNova beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Envista?

Envista (NYSE:NVST) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Envista currently has a consensus target price of $28.83, suggesting a potential upside of 24.09%. PROCEPT BioRobotics has a consensus target price of $41.45, suggesting a potential upside of 58.71%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43

Envista has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

In the previous week, PROCEPT BioRobotics had 3 more articles in the media than Envista. MarketBeat recorded 9 mentions for PROCEPT BioRobotics and 6 mentions for Envista. PROCEPT BioRobotics' average media sentiment score of 0.98 beat Envista's score of 0.54 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envista has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.39	$47M	$0.41	56.67
PROCEPT BioRobotics	$308.05M	4.83	-$95.57M	-$1.82	N/A

Envista has a net margin of 2.41% compared to PROCEPT BioRobotics' net margin of -31.82%. Envista's return on equity of 7.11% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 1.0% of Envista shares are held by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Envista and PROCEPT BioRobotics tied by winning 8 of the 16 factors compared between the two stocks.

Get PROCEPT BioRobotics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRCT vs. The Competition

Export

Metric	PROCEPT BioRobotics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.49B	$6.69B	$6.25B	$12.29B
Dividend Yield	N/A	1.76%	2.81%	5.30%
P/E Ratio	-14.35	49.11	20.63	25.26
Price / Sales	4.83	68.87	555.02	73.57
Price / Cash	N/A	24.43	27.48	37.27
Price / Book	3.99	6.45	9.80	6.71
Net Income	-$95.57M	$158.81M	$3.57B	$336.00M
7 Day Performance	-1.25%	-2.05%	-1.04%	-0.68%
1 Month Performance	3.90%	-6.28%	-2.62%	-0.06%
1 Year Performance	-55.02%	-4.45%	33.54%	30.62%

PROCEPT BioRobotics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRCT PROCEPT BioRobotics	4.0534 of 5 stars	$26.12 flat	$41.45 +58.7%	-55.0%	$1.49B	$308.05M	N/A	430	Positive News
BLCO Bausch + Lomb	4.3155 of 5 stars	$16.10 -0.5%	$18.08 +12.3%	+36.7%	$5.77B	$5.21B	N/A	13,000	Positive News
STVN Stevanato Group	3.4073 of 5 stars	€18.29 +0.1%	N/A	-25.9%	€5.54B	€1.34B	31.00	6,010
IRTC iRhythm Technologies	4.4641 of 5 stars	$116.84 -3.2%	$193.38 +65.5%	-19.1%	$3.97B	$747.14M	N/A	2,400	Positive News
LIVN LivaNova	2.5263 of 5 stars	$70.09 -2.5%	$77.22 +10.2%	+57.7%	$3.95B	$1.39B	35.94	3,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRCT) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. BLCO, STVN, IRTC, LIVN, and NVST

How does PROCEPT BioRobotics compare to Bausch + Lomb?

Summary

How does PROCEPT BioRobotics compare to Stevanato Group?

Summary

How does PROCEPT BioRobotics compare to iRhythm Technologies?

Summary

How does PROCEPT BioRobotics compare to LivaNova?

Summary

How does PROCEPT BioRobotics compare to Envista?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. BLCO, STVN, IRTC, LIVN, and NVST

How does PROCEPT BioRobotics compare to Bausch + Lomb?

Which has higher earnings & valuation, PRCT or BLCO?

Do analysts rate PRCT or BLCO?

Do insiders and institutionals hold more shares of PRCT or BLCO?

Is PRCT or BLCO more profitable?

Which has more volatility & risk, PRCT or BLCO?

Does the media refer more to PRCT or BLCO?

Summary

How does PROCEPT BioRobotics compare to Stevanato Group?

Which has higher earnings & valuation, PRCT or STVN?

Do analysts rate PRCT or STVN?

Do insiders and institutionals hold more shares of PRCT or STVN?

Is PRCT or STVN more profitable?

Which has more volatility & risk, PRCT or STVN?

Does the media refer more to PRCT or STVN?

Summary

How does PROCEPT BioRobotics compare to iRhythm Technologies?

Do analysts rate IRTC or PRCT?

Which has better valuation & earnings, IRTC or PRCT?

Which has more volatility and risk, IRTC or PRCT?

Do institutionals & insiders believe in IRTC or PRCT?

Does the media favor IRTC or PRCT?

Is IRTC or PRCT more profitable?

Summary

How does PROCEPT BioRobotics compare to LivaNova?

Do analysts rate PRCT or LIVN?

Which has stronger valuation and earnings, PRCT or LIVN?

Which has more risk and volatility, PRCT or LIVN?

Do insiders and institutionals believe in PRCT or LIVN?

Does the media refer more to PRCT or LIVN?

Is PRCT or LIVN more profitable?

Summary

How does PROCEPT BioRobotics compare to Envista?

Do analysts prefer NVST or PRCT?

Which has more volatility and risk, NVST or PRCT?

Does the media prefer NVST or PRCT?

Which has preferable earnings and valuation, NVST or PRCT?

Is NVST or PRCT more profitable?

Do insiders and institutionals hold more shares of NVST or PRCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools